AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 265
- Registration Number
- NCT01544179
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Dapagliflozin/metformin IR FDC tablet fedDrug: Dapagliflozin/metformin IR FDC tablet fasted
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 71
- Registration Number
- NCT01535677
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary
- Conditions
- SchizophreniaAffective Symptoms
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2153
- Registration Number
- NCT01534936
- Locations
- 🇭🇺
Research Site, Veszprem, Hungary
Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118
- Conditions
- Drug Induced Constipation
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT01533155
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01533870
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT01530334
- Locations
- 🇮🇹
Research Site, Verona, Italy
PET Study in Parkinson's Disease Patients
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Placebo for AZD3241 25 mgDrug: ER tablet 25 mg AZD3241Drug: Placebo for AZD3241 100 mgDrug: ER tablet 100 mg AZD3241
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01527695
- Locations
- 🇸🇪
Reserach Site, Stockholm, Sweden
🇸🇪Research Site, Vallingby, Sweden
Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
- Conditions
- Stage IIIB/IVNon-Small Cell Lung Cancer
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT01525199
- Locations
- 🇦🇷
Research Site, Tucuman, Argentina
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Saxagliptin/Metformin XR FDC
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT01525225
- Locations
- 🇺🇸
Childrens Hospital Of Pittsburgh Of Upmc, Pittsburgh, Pennsylvania, United States
🇺🇸Promedica Toledo Children'S Hospital, Toledo, Ohio, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
PK Study of Dapagliflozin in Pediatric Subjects With T2DM
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT01525238
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Lsuhsc-Shreveport, Shreveport, Louisiana, United States
🇺🇸Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States